Join
Live feed
·
PRReleasevia Quantisnow
Zenas BioPharma Inc. logo

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

ByQuantisnow·Wall Street's wire, on your screen.
ZBIO· Zenas BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZBIO (Zenas BioPharma Inc.) and more on Quantisnow.